OBJECTIVE To define the morphological criteria of perforated atrial septal aneurysms suitable for closure by a transcatheter device.
METHODS A retrospective analysis of all consecutive patients with atrial septal aneurysm and one or more perforations presenting between May 1997 and June 1999. The aneurysms were classified as: aneurysm with persistent foramen ovale (type A); aneurysm with single atrial septal defect (type B); aneurysm with two perforations requiring more than one device for closure (type C); and aneurysm with multiple perforations (type D).
PATIENTS Data from 50 patients aged 5–78 years (mean 43 years) were analysed; 32 had systemic thromboembolism or transient ischaemic attacks, eight presented with dyspnoea on exercise, and 10 were discovered incidentally but had significant left to right shunt and right ventricular volume overload.
RESULTS In all 18 patients with aneurysm and persistent foramen ovale (type A), transcatheter closure was possible. In nine with aneurysm and atrial septal defect (type B), five defects were closed and four required surgery. Device closure was achieved in all 10 patients with aneurysms and two perforations (type C), but four had a residual shunt. Thirteen patients with multiple perforated aneurysms (type D) underwent surgery.
CONCLUSIONS This classification of morphology of perforations of aneurysm is clinically useful for selecting patients for treatment by transcatheter devices.
- atrial septum
- transcatheter device
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
The prevalence of atrial septal aneurysm is reported to be 2.2%.1 Perforated aneurysms may be associated with a significant left to right shunt and present like an atrial septal defect,2 or the shunt may be small and clinically present as systemic thromboembolic events caused either by thrombus formation inside the aneurysm or by paradoxical embolism.3 In some patients devoid of clinical symptoms, the aneurysm may be detected incidentally on medical screening.4 There are no universally accepted treatment strategies, and recommendations—which vary from country to country—include anticoagulation5 or closure, depending on the clinical symptoms, the morphology of the aneurysm, and the presence and number of perforations.6Recent improvements in transcatheter devices for closing atrial septal defects have led to attempts to use this technique for the treatment of perforated aneurysms.7 ,8 Our aim in this study was to analyse the morphology of perforated atrial septal aneurysms to determine which of them might be suitable for closure by transcatheter device placement.
Consecutive patients with a perforated atrial septal aneurysm as an isolated congenital malformation of the heart and who presented between May 1997 and June 1999 at our institution were included in this retrospective study. The start date represents the day of the first implantation of an Amplatzer septal occluder at our centre.9 Atrial septal aneurysm was considered to be present10 if there was circumscribed bulging in the atrial septum, with a base width of at least 15 mm (or 8 mm/m2body surface area in children) and a depth of at least 15 mm (or 8 mm/m2 body surface area in children), or if there was an oscillating membrane with excursions of 15 mm or more. In all patients, diagnosis was made by transthoracic echocardiography using commercially available sector scanners (Vingmed System V, Horten, Norway). All patients also underwent an evaluation by transoesophageal echocardiography (TOE). Fifty patients were identified. In 22 of these, a history of previous thromboembolic events with cerebral infarction had been documented by cranial computed or magnetic resonance tomography, and a further 10 had recurrent transient ischaemic attacks. Eight presented with dyspnoea on exercise. The remaining 10 patients were discovered incidentally on medical screening, and had echocardiographic signs of right ventricular volume overload. Two patients had atrial flutter on presentation, while the remainder were in sinus rhythm.
All patients underwent cardiac catheterisation on the basis that the perforated atrial septal aneurysm would be treated with a transcatheter device. Standard fluid filled catheters were employed, and the pulmonary (Qp) to systemic (Qs) flow ratio was measured by oximetry using the Fick principle. The size of the interatrial communications was determined with balloon catheters, as described elsewhere.9 ,11 All patients had TOE as part of the routine protocol during balloon sizing, which allowed the detection and localisation of additional defects by colour flow mapping during balloon occlusion.9 On the basis of the findings at TOE, the aneurysms were classified as follows (fig 1A):
atrial septal aneurysm with patent foramen ovale (type A);
atrial septal aneurysm with single atrial septal defect (type B);
atrial septal aneurysm with two perforations or few perforations located in not more than two clusters requiring placement of more than one device (type C); and
atrial septal aneurysm with multiple perforations located in more than two areas of the atrial septum (type D).
Closure of interatrial communications by transcatheter device placement was attempted in all patients. We used three devices: the Amplatzer septal (ASD) occluder, the Amplatzer persistent foramen ovale (PFA) occluder, and the Cardio-Seal device. The technical details of the implantation of the Cardio-Seal (Nitinol Medical Technologies, Boston, Massachusetts, USA) and Amplatzer devices (AGA Medical Corporation, Golden Valley, Minnesota, USA) have been described elsewhere.8 ,9 ,12 A 7–14 French long sheath was used to deliver the Amplatzer or Cardio-Seal devices. TOE was performed in all patients using a multiplane transoesophageal probe interfaced with a Vingmed 800 sector scanner or a monoplane probe interfaced with a Siemens Sonoline 1200 sector scanner (Siemens, Erlangen, Germany) to monitor device placement. All patients were sedated with intravenous midazolam 0.1–0.2 mg/kg immediately before entering the catheterisation laboratory. During the procedure, sedation was achieved by a continuous infusion of propofol 3–5 mg/kg/h. Neither endotracheal intubation nor mechanical ventilation was required in any patient. All patients in whom transcatheter device closure of defects was achieved were treated with aspirin 3–5 mg/kg/day for six months.
All the patients, or their parents, gave written informed consent for defect closure with either the Amplatzer or the Cardio-Seal device. The implantation protocol was approved by the local institutional ethics committee.
Data are expressed as mean (SD) or median (range). The 50 patients were treated at a mean age of 43 (17) years (range 5–78 years); four were under 18 years of age. In the 18 who presented without stroke but with signs of right ventricular volume overload, the mean (SD) pulmonary (Qp) to systemic (Qs) flow ratio was 2.1 (0.6). In the 18 patients with atrial septal aneurysm and persistent foramen ovale (type A), transcatheter closure was possible in all (figs 2 and 3) using the Amplatzer PFO occluder (n = 9, fig 1B), the Amplatzer ASD occluder (n = 8), or the Cardio-Seal device (n = 1).
In the nine patients with atrial septal aneurysm and atrial septal defect (type B), an Amplatzer ASD occluder was placed in five (figs 1B and 2). In the remaining four patients, the defects were located too close to the mitral valve in two patients and were too large (> 28 mm and > 34 mm diameter) for closure with the available devices at that time in the other two. These patients underwent surgery. In the five who were successfully treated with an Amplatzer ASD occluder, a small part of the atrial septal aneurysm remained uncovered by the device, but was stabilised by the splinting effect of the occluder.
In the 10 patients with atrial septal aneurysm and two perforations, or perforations located in not more than two clusters that required implantation of more than one device (type C), seven were treated with an Amplatzer and three with a Cardio-Seal device. A single device was placed in five of the 10 patients (two Amplatzer, three Cardio-Seal), with evidence of residual shunts (fig 2). One of these patients was treated with a second device (Cardio-Seal) 12 months later, and complete occlusion was achieved. Four others were scheduled for implantation of a second device. In five patients, two Amplatzer devices were placed in one session (figs 1 and 4B); no residual shunts were detected and the devices splinted the septum well.
In the 13 patients with atrial septal aneurysms associated with multiple perforations (type D), the morphology of the perforations was thought to be unsuitable for closure by a transcatheter device (fig 5). All these patients underwent surgery and had the perforated aneurysm excised. The missing part of the atrial septum was subsequently replaced with a pericardial patch. All these patients had an uneventful recovery. There were no complications of transcatheter device placements, such as embolisation or rhythm disturbances.
During the mean follow up period of 14 (12) months (range 5–30 months), which represents 477 patient months in those treated by device placement, all devices stayed in place. In all patients treated successfully by the catheter technique after a thromboembolic event (n = 23), no further thromboembolic events occurred during a mean follow up period of 13 (11) months (range 5–30 months), which represents 295 patient months. In the four patients with residual shunts (fig 2), the shunts did not close spontaneously and the placement of a second device is planned.
Our data show that perforated atrial septal aneurysms can be successfully treated by transcatheter device placement, provided the interatrial communication is not too large or too close to the mitral valve and there are no more than two perforations or small perforations in clusters of two. The latter may require the placement of two devices, while aneurysms with multiple perforations may only rarely be treatable with the currently available transcatheter devices, and may require lifelong anticoagulation or surgery. In this retrospective analysis, device closure of perforated atrial septal aneurysms was successfully accomplished in 58% of unselected cases.
MORPHOLOGY OF ANEURYSM RELEVANT TO TREATMENT
Previous investigators have used different criteria for the diagnosis of atrial septal aneurysm and have proposed different classifications.10 ,13 ,14 On the basis of the success of treatment by transcatheter device placement, we propose a clinically useful classification to facilitate the selection of symptomatic patients for device closure. The morphological features that form the basis of this classification and are relevant for successful interventional treatment are the location, number, and size of the interatrial communications. In our opinion, it is not relevant whether the aneurysm is predominantly bulging to the right or the left side of the interatrial septum,13 because we only advocate the treatment of patients with either a history of stroke and a TOE documented potential of right to left shunt through interatrial communications,15 or a significant left to right shunt that results in right ventricular volume overload, such as an atrial septal defect that is not associated with an aneurysm. While there is agreement on the need for closure of atrial septal defects with left to right shunt (Qp/Qs) greater than 1.5:1 (irrespective of the presence or absence of aneurysm), even when incidentally diagnosed in adults,16 treatment strategies for patients with perforated atrial septal aneurysm and cryptogenic stroke need to be defined. Our policy of treating patients with perforated atrial septal aneurysm and a history of transient ischaemic attacks or cryptogenic stroke may represent overtreatment,17 but is also practised in other centres.6 ,15 ,18 ,19 As not all of our patients with a single unexplained neurological event had documented peripheral venous thrombosis or a history of pulmonary embolism, we need a better definition of treatment criteria for the future. In our opinion, this may be achieved by prospective multicentre trials designed to establish treatment rationales based on the true prevalence of perforated atrial septal aneurysms in the general population, the rate of complications, and results of alternative medical treatment such as anticoagulation.
TRANSCATHETER DEVICES USED IN THIS STUDY
Since May 1998, we have preferred to use the Amplatzer PFO occluder or the Cardio-Seal device to treat atrial septal aneurysms with small perforations, as they have a better splinting effect and may thus stabilise the aneurysm better than the Amplatzer ASD occluder. Owing to the rotation symmetry, the Amplatzer occluder is easier to implant than the Cardio-Seal device in complex aneurysms. The limbs of the Cardio-Seal occluder can be trapped through additional perforations, which complicates the delivery of a second device. However, a combination of an Amplatzer ASD occluder (larger disc on the left atrial side) and an Amplatzer PFO occluder (large disc on the right atrial side) forms a predictable and stable splint within a multiperforated aneurysm of type C (fig 4B).
Recent reports have linked the devices used in our patients to real or potential complications. Fracture of the limbs of the Cardio-Seal device has been found to occur, and there is some debate about the biological effects of nitinol.20 Clearly, a longer follow up is required for an accurate assessment of the true incidence of complications for these devices. When comparing the side effects from surgery and device implantation for treatment of atrial septal defects in the short term, the Amplatzer device is certainly as effective as surgery.21
We analysed our data on atrial septal aneurysm treatment retrospectively. We have not performed a randomised study assigning patients with a history of neurological complications and perforated atrial septal aneurysms to a protocol of closure versus no closure. A substantially longer follow up period is required to study the effect of closure of perforations on the incidence of systemic thromboembolism in this group. However, the other group of patients treated with transcatheter device closure, which constituted 36% of our cases, had significant left to right shunt and required closure irrespective of the presence or absence of atrial septal aneurysm. We did not perform a formal comparison of the three different catheter delivered devices that we used, but relied on experience and clinical acumen to decide which device or combination of devices was most suitable for closure of the perforation or perforations in each individual patient.
Despite the limitations of this study, we conclude that our proposed classification of morphology of perforations of atrial septal aneurysm is clinically useful for selecting symptomatic patients for treatment by transcatheter devices. While there is general agreement that patients with perforated atrial septal aneurysm and associated significant left to right shunts with right ventricular volume overload should be treated, further prospective studies are required to define the need for treatment of such aneurysms in patients with a history of systemic thromboembolism.
We are grateful for editorial assistance from Tonie Derwent.